10-Q: FitLife Brands Q2 Profit Drops Amid Revenue Decline

FitLife Brands reported a significant decline in net income and revenue for Q2 2025, primarily due to decreased performance in its MRC and MusclePharm brands, despite a strategic acquisition of Irwin Naturals post-quarter end.

Summary

• Revenue for the three months ended June 30, 2025, decreased by 5% to $16.1 million, down from $16.9 million in the prior year.
• Net income for the three months ended June 30, 2025, fell by 34% to $1.7 million, compared to $2.6 million in the same period last year.
• Gross profit decreased by 9% to $6.9 million for the quarter, with gross margin declining to 42.8% from 44.8%.
• For the six months ended June 30, 2025, revenue decreased by 4% to $32.1 million, and net income decreased by 21% to $3.8 million.
• Legacy FitLife brands saw a 7% revenue increase in Q2 2025, driven by a 17% increase in online revenue and a 1% increase in wholesale revenue.
• MRC revenue decreased by 16% in Q2 2025, primarily due to a drop in traffic to its product listing pages on Amazon, with Dr. Tobias brand revenue down 16% and skin care brands down 20%.
• MusclePharm revenue decreased by 4% in Q2 2025, with wholesale revenue down 6% and online revenue down 3%, impacted by promotional investments.
• Merger and acquisition related expenses significantly increased to $696,000 in Q2 2025 from $24,000 in Q2 2024, driven by the Irwin acquisition.
• Post-quarter end, on August 8, 2025, FitLife Brands acquired substantially all assets of Irwin Naturals for approximately $42.5 million, funded by a new $40.6 million term loan, $6.0 million from a new $10.0 million revolving line of credit, and available cash.
• The company's existing debt of $10.9 million was paid off and replaced with the new financing for the Irwin acquisition.
• A 2-for-1 stock split was effected on February 7, 2025, and the share repurchase program was extended on May 13, 2025, authorizing up to $5.0 million in repurchases over 24 months, though no repurchases occurred in the period.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in key financial metrics (revenue, net income, gross profit) for both the quarter and six-month periods. While the Irwin Naturals acquisition is a strategic positive, it introduces substantial new debt and integration risks. The decline in performance of MRC and MusclePharm brands also weighs on the outlook, despite growth in Legacy FitLife. The increased M&A expenses further impacted profitability.

Positives

• Legacy FitLife brands demonstrated strong growth, with a 7% increase in revenue for Q2 2025, including a 17% increase in online revenue.
• Advertising and marketing expenses decreased by 10% in Q2 2025 due to targeted efforts to rationalize less effective campaigns.
• The company maintained positive working capital of $9.2 million as of June 30, 2025, an increase from $6.8 million at December 31, 2024.
• Successful acquisition of Irwin Naturals post-quarter end, a strategic move to expand product offerings and market presence.
• Management believes current cash flow from operations and available borrowings will be sufficient for liquidity over the next twelve months.

Negatives

• Overall revenue decreased by 5% for the quarter and 4% for the six months ended June 30, 2025, compared to the prior year periods.
• Net income significantly declined by 34% for the quarter and 21% for the six months ended June 30, 2025.
• Gross profit and gross margin decreased across both the three-month and six-month periods, impacted by product mix, promotional investments, and tariffs.
• MRC brand revenue decreased by 16% in Q2 2025, primarily due to reduced Amazon traffic, impacting overall performance.
• MusclePharm revenue decreased by 4% in Q2 2025, with promotional investments leading to lower gross margins for the brand.
• Merger and acquisition related expenses increased substantially to $696,000 in Q2 2025, reflecting costs associated with the Irwin acquisition.
• Cash and cash equivalents decreased from $4.5 million at December 31, 2024, to $1.5 million at June 30, 2025, largely due to the $5.0 million deposit for the Irwin acquisition.
• Cash provided by operating activities decreased significantly to $3.5 million for the six months ended June 30, 2025, from $6.6 million in the prior year period.

Risks

• Dependence on cash flow from operations and the Line of Credit to satisfy working capital requirements, with no assurance of sufficiency.
• Potential for material adverse harm to the business if unable to generate sufficient revenue, if additional capital is unavailable, or if unable to secure additional working capital through equity or debt issuance.
• Exposure to fluctuations in foreign currency exchange rates, particularly with Canadian subsidiaries.
• Interest rate risk related to floating-rate borrowings under the credit agreements.
• Customer concentration risk, with GNC accounting for a significant portion of net sales (22% in Q2 2025, 19% for six months ended June 30, 2025).
• Vendor concentration risk, with one vendor accounting for over 10% of consolidated accounts payable and two vendors for over 10% of inventory-related purchases.
• Impact of tariffs on skin care products sold in Canada affecting gross margins.
• Significant price fluctuations in the company's common stock could impact the fair value of the reporting unit and potentially lead to goodwill impairment.

Future Outlook

Management anticipates that cash derived from operations and existing cash reserves, along with available borrowings under the Line of Credit, will be sufficient to provide for the company's liquidity for the next twelve months. The company has no current intention to raise additional working capital through the sale of equity or debt securities. Promotional efforts for the MusclePharm brand are expected to continue, which may cause fluctuations in gross and contribution margins.

Management Comments

• "The decrease in revenue for the three months ended June 30, 2025 compared to the prior period is primarily due to declining revenue from MRC, partially offset by an increase in Legacy FitLife revenue."
• "The decrease in gross margin is primarily attributable due to product mix, continued MusclePharm promotional investment, and the impact of tariffs on the Company's skin care products being sold in Canada."
• "The 10% decrease [in advertising and marketing] is the result of targeted efforts to rationalize the Company's advertising spend on less effective advertising campaigns."
• "The decrease in net income for the three months ended June 30, 2025 compared to the same period in 2024 was primarily attributable to lower revenue and gross profit as well as an increase in merger and acquisition related expense."
• "Management currently has no intention to raise additional working capital through the sale of equity or debt securities and believes that the cash flow from operations and available borrowings under the Line of Credit will provide sufficient capital necessary to operate the business over the next twelve months."
• "In the event the Company fails to achieve positive cash flow from operations, additional capital is unavailable under the terms of the Line of Credit, and management is otherwise unable to secure additional working capital through the issuance of equity or debt securities, the Company's business would be materially and adversely harmed."

Industry Context

The nutritional supplements and wellness products industry continues to see a significant shift towards online sales, with FitLife Brands generating approximately 65-66% of its net revenue from e-commerce platforms. The company's strategy involves growth through acquisitions, as evidenced by the recent MusclePharm and Irwin Naturals deals, aiming to expand its brand portfolio and market reach. However, competition in the e-commerce space, particularly on platforms like Amazon, can impact brand performance, as seen with the decline in MRC's revenue due to reduced traffic.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmarking.
• The company's gross margin of 42.8% in Q2 2025, while declining, is generally in line with the broader consumer packaged goods and health supplements industry, which can vary widely based on product mix, distribution channels, and brand positioning.
• The significant reliance on online sales (65% of net revenue) aligns with the growing trend of direct-to-consumer and e-commerce penetration in the health and wellness sector.
• The strategic acquisition of Irwin Naturals, a known brand, indicates a common industry approach to consolidate market share and diversify product offerings, especially within a fragmented supplements market.

Corporate Governance

Stakeholder Impact

• Shareholders: Experienced a 2-for-1 stock split, potentially increasing liquidity. However, net income and EPS declined, and the company took on significant new debt for the Irwin acquisition, which could impact future returns and risk profile.
• Employees: No direct impact mentioned, but acquisitions often involve integration and potential restructuring.
• Customers: Continued availability of products through various channels (GNC, online). New product launches (MusclePharm Pro Series) and brand acquisitions (Irwin Naturals) expand offerings.
• Suppliers: One vendor accounted for over 10% of accounts payable, and two vendors for over 10% of inventory purchases, indicating concentration risk.
• Creditors: Existing debt was paid off and replaced with new, larger term loans and credit lines, increasing the company's overall leverage.

Next Steps

• Integration of Irwin Naturals acquisition and determination of fair value of its tangible and intangible assets.
• Commencement of quarterly principal payments on the new Term Loan starting December 31, 2025.
• Continued targeted promotional efforts for the MusclePharm brand.
• Ongoing evaluation of internal control over financial reporting and impairment indicators for goodwill and intangible assets.

Key Dates

Recommendation

The company's Q2 2025 financial results show a clear decline in revenue, gross profit, and net income, indicating operational challenges, particularly with the MRC and MusclePharm brands. While the acquisition of Irwin Naturals is a significant strategic move that could drive future growth and diversification, it also introduces substantial new debt and the inherent risks of integration. The increased leverage and the current negative financial trends suggest a cautious approach. A 'Hold' recommendation is appropriate as investors should monitor the successful integration of Irwin Naturals and its impact on future financial performance, as well as the company's ability to reverse the declining trends in its existing brands and manage its increased debt load.

Keywords

Nutritional Supplements, Wellness Products, SEC Filing, Quarterly Report, Financial Performance, Acquisition, Irwin Naturals, MusclePharm, MRC, Legacy FitLife, E-commerce, Wholesale, Gross Margin, Net Income, Revenue, Debt Financing, Stock Split, Share Repurchase, GNC